A Food and Drug Administration committee backed a cancer blood test called Galleri but was split on how well it works. The test is awaiting a final decision by the FDA.

Telling more people they have cancer is not progress; progress is having fewer people die from cancer,” H. Gilbert Welch ...

A controversial blood test aimed at detecting multiple cancers was backed by a U.S. Food and Drug Administration panel this week. Here's what to know.

The US Food and Drug Administration has approved a blood test to be used for colorectal cancer screening among average-risk adults 45 and older. The maker of the test, Palo Alto, California-based ...

Whether screening with blood-based early-detection tests for multiple cancers in addition to usual care has clinical utility is unknown. In a randomized, controlled trial conducted in England, we ...

GRAIL (GRAL) stock hits a 52-week high after an FDA advisory panel backs Galleri, a multi-cancer blood test developed by the company. Read more here.

Colorectal cancer is the third most diagnosed cancer in adults in the United States. Early detection could prevent more than 90% of colorectal cancer–related deaths, yet more than one third of the ...